11 withdrawn. 11 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Withdrawn 11 |
| Phase 3 | 3 | Withdrawn 3 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy PO BRC-003 (High Cannabidiol Cannabis Extract), Placebo - Post-traumatic Epilepsy | Phase 2 | Withdrawn | Dr. Paul Lyons | 2024-11-01 | 2025-04-24 | |
| Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies MGCND00EP1, Placebo, ECG - Resistant Epilepsy, Drug, Adolescent Epilepsy | Phase 2 | Withdrawn | MGC Pharmaceuticals d.o.o | 2024-05-30 | 2024-06-03 | |
| ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures ENX-101 - Focal Epilepsy | Phase 2 | Withdrawn | Engrail Therapeutics INC | 2022-09-01 | 2023-07-06 | |
| ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors ES-481 - Epilepsy; Seizure | Phase 2 | Withdrawn | ES Therapeutics Australia Pty Ltd | 2021-03-25 | 2022-04-06 | |
| Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus Traditional Treatment (Group T), Ketamine Infusion (Group K) - Refractory Epilepsy | Phase 2 / Phase 3 | Withdrawn | University of Alabama at Birmingham | 2017-05-04 | 2021-05-21 | |
| Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012 Pyridoxine, Sodium Valproate, Phenytoin - Nodding Syndrome | Phase 2 | Withdrawn | Centers for Disease Control and Prevention | 2016-02-01 | 2022-05-18 | |
| Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) Everolimus - Sturge Weber Syndrome | Phase 2 | Withdrawn | Baylor College of Medicine | 2014-04-01 | 2016-05-05 | |
| Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy modified Atkins diet, no dietetic input - Infantile Spasms | Phase 2 / Phase 3 | Withdrawn | Lady Hardinge Medical College | 2012-02-01 | 2013-04-09 | |
| Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy Botanical extract from Passiflora incarnata - Partial Epilepsy | Phase 2 | Withdrawn | Oregon Health and Science University | 2009-09-01 | 2019-08-13 | |
| A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures Seletracetam - Epilepsies, Partial | Phase 2 / Phase 3 | Withdrawn | UCB Pharma | 2008-05-01 | 2012-05-28 | |
| GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures GW273225 - Epilepsy | Phase 2 | Withdrawn | GlaxoSmithKline | 2006-07-01 | 2013-04-04 |
Epilepsies, Partial (3) · Seizures (3) · Drug Resistant Epilepsy (2) · Epilepsy, Post-Traumatic (1) · Glaucoma (1) · Nodding Syndrome (1) · Port-Wine Stain (1) · Spasms, Infantile (1) · Sturge-Weber Syndrome (1)
Brain Diseases (11) · Central Nervous System Diseases (11) · Nervous System Diseases (11) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Epilepsy, Generalized (2) · Angiomatosis (1) · Brain Injuries (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniocerebral Trauma (1) · Epileptic Syndromes (1)
nabiximols (2) · Barbiturates (1) · Benzodiazepines (1) · Blood Specimen Collection (1) · Cannabinoids (1) · Electrocardiography (1) · Electroencephalography (1) · Everolimus (1) · Hematologic Tests (1) · Ketamine (1) · Phenytoin (1) · Propofol (1) · Pyridoxine (1) · Seletracetam (1) · Sensitivity Training Groups (1)
Baylor College of Medicine (1) · Centers for Disease Control and Prevention (1) · Dr. Paul Lyons (1) · ES Therapeutics Australia Pty Ltd (1) · Engrail Therapeutics INC (1) · GlaxoSmithKline (1) · Lady Hardinge Medical College (1) · MGC Pharmaceuticals d.o.o (1) · Oregon Health and Science University (1) · UCB Pharma (1) · University of Alabama at Birmingham (1)
United States (6) · India (1) · Israel (1) · Slovenia (1) · Uganda (1)
Angus A Wilfong, MD (1) · Barbara Bennett, PhD (1) · Paul D Lyons, MD. PhD (1) · Rubi Zomer (1) · Scott Dowell, MD (1) · Siegward M Elsas, M.D. (1) · Terence O'Brien, MD (1) · Vinodkumar Singh, MD (1)
K23AT001933 (1)